Relay Therapeutics Stock In Focus As Phase 3 Trial Begins
- X-Chem reported that Relay Therapeutics has started a Phase 3 clinical trial for zovegalisib, or RLY-2608, a PI3Ka inhibitor that originated from X-Chem's DNA-encoded library collaboration with the biotech.
- The move into Phase 3 testing highlights how Relay Therapeutics is leaning on external discovery platforms to advance its oncology pipeline while sharing development risk with partners.
- Now the focus turns to how Relay Therapeutics' investment narrative could shift as zovegalisib progresses into Phase 3 following the X-Chem collaboration.
What Is Relay Therapeutics' Investment Narrative?
For anyone considering Relay Therapeutics, the core belief is pretty simple. You need to think this platform approach to precision oncology can turn expensive R&D into a pipeline that justifies years of losses. Zovegalisib moving into Phase 3 through the X-Chem collaboration feeds that view. It shows Relay is willing to lean on external discovery tools while focusing internal resources on development, partnerships and execution instead of trying to own every step of the process.
The near term story still revolves around clinical milestones, cash burn and access to capital. Shares have pulled back over the past month, yet the stock is up sharply year to date and analysts see meaningful upside to the current US$18.03 price. Forecast revenue growth above 60% a year and an unprofitable income statement set a high bar for Relay Therapeutics to keep funding an oncology pipeline that now includes a Phase 3 program tied to X-Chem.
Even so, there is a less obvious pressure point that could matter quite a lot if ...
There's only one way to know the right time to buy, sell or hold Relay Therapeutics. Head to Simply Wall St's company report for the latest analysis of Relay Therapeutics's Fair Value.
Exploring Other Perspectives
The bullish twist on Relay Therapeutics is all about zovegalisib as a revenue engine. Highest forecast analysts were modeling revenue climbing to about US$170.5m and earnings flipping to a US$29.4m profit by 2029, from a US$286.0m loss, and even accepting a very rich 362.7x P/E. Views can differ sharply. Treat this Phase 3 news as a fresh reason to compare these optimistic assumptions with your own expectations.
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Relay Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Relay Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Relay Therapeutics' overall financial health at a glance.
Looking For More Ideas Beyond Relay Therapeutics?
If you want to cross check Relay Therapeutics against other opportunities, the Simply Wall St Screener can help you quickly sort through businesses with very different profiles and risk levels.
- For investors who care most about financial resilience, start with a list of solid balance sheet and fundamentals (23 results) that can handle tougher conditions without relying heavily on new funding.
- If you want potential upside with less volatility, filter for 31 resilient stocks with low risk scores that combine sturdier fundamentals with more measured price swings.
- When you are hunting for future leaders earlier in their journey, scan through 16 high quality undiscovered gems that have strong underlying metrics but attract less day to day attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com